6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
7m ago	Ultra Clean Announces Retirement of the Chief Financial Officer Sheri Savage
7m ago	GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
7m ago	Rush Enterprises, Inc. Reports First Quarter 2026 Results, Announces $0.19 Per Share Dividend
8m ago	EVgo to Report First Quarter 2026 Results on May 5
8m ago	Sound Financial Bancorp, Inc. Q1 2026 Results

About

Inhibikase Therapeutics Inc (NASDAQ:IKT) — investor relations, events, news, and company updates on 6ix.

Latest News

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Financials

Revenue

$1

Market Cap

$237.66 M

EPS

-0.49

Community Chat

Ask AI